Glycerol phenylbutyrate explained
| Tradename: | Ravicti |
| Routes Of Administration: | By mouth |
| Atc Prefix: | A16 |
| Atc Suffix: | AX09 |
| Legal Ca: | Rx-only |
| Legal Ca Comment: | [1] |
| Legal Us: | Rx-only |
| Legal Us Comment: | [2] |
| Legal Eu: | Rx-only |
| Cas Number: | 611168-24-2 |
| Pubchem: | 10482134 |
| Drugbank: | DB08909 |
| Chemspiderid: | 8657541 |
| Unii: | ZH6F1VCV7B |
| Chembl: | 2105745 |
| Iupac Name: | 1,2,3-Propanetriyl tris(4-phenylbutanoate) |
| C: | 33 |
| H: | 38 |
| O: | 6 |
| Smiles: | C1=CC=C(C=C1)CCCC(=O)OCC(COC(=O)CCCC2=CC=CC=C2)OC(=O)CCCC3=CC=CC=C3 |
| Stdinchi: | 1S/C33H38O6/c34-31(22-10-19-27-13-4-1-5-14-27)37-25-30(39-33(36)24-12-21-29-17-8-3-9-18-29)26-38-32(35)23-11-20-28-15-6-2-7-16-28/h1-9,13-18,30H,10-12,19-26H2 |
| Stdinchikey: | ZSDBFLMJVAGKOU-UHFFFAOYSA-N |
Glycerol phenylbutyrate, sold under the brand name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body.[3] It is an FDA-approved prescription drug in the US.[4] It was developed by Hyperion Therapeutics based on the existing medication sodium phenylbutyrate, and received approval in February 2013.[5]
Society and culture
Economics
Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales).[6]
Notes and References
- Web site: Health Canada New Drug Authorizations: 2016 Highlights . . 14 March 2017 . 7 April 2024.
- Web site: Ravicti- glycerol phenylbutyrate liquid . DailyMed . 13 September 2021 . 4 July 2023 . 3 May 2023 . https://web.archive.org/web/20230503005405/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=900e7dc0-9afe-4f50-80de-90567bb78519 . live .
- FDA approves new drug for the chronic management of some urea cycle disorders . 1 February 2013 . U.S. Food and Drug Administration . 2013-04-01 . https://web.archive.org/web/20130307230112/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm337639.htm . 2013-03-07 . dead .
- Web site: Drugs@FDA . FDA Approved Drug Products: Ravicti . U.S. Food and Drug Administration . 18 February 2018 . 29 June 2017 . https://web.archive.org/web/20170629071243/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203284 . live .
- Herder M . Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada . Journal of Law and the Biosciences . 3 . 1 . 158–166 . April 2016 . 27774236 . 5033429 . 10.1093/jlb/lsv060 .
- Web site: Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B. 30 March 2015. Genetic Engineering & Biotechnology News. 18 February 2018. 26 August 2017. https://web.archive.org/web/20170826235806/http://www.genengnews.com/gen-news-highlights/horizon-pharma-to-acquire-hyperion-therapeutics-for-1-1b/81251089. live.
